Turkish Decree Places New Caps On Drug Price Increases
In order to help curb the drugs bill, the Turkish Social Security Institution has decided to restrict the level of price increases that can be made on pharmaceutical products when the prices of those products are increased in reference or non-reference countries.
You may also be interested in...
Localization Barriers To Trade In Medicines And Health Care Products: The Tricky Business Of Balancing Competing Interests
There is a clear tension at a global level between the need for the international movement of pharmaceutical products and the need for access to affordable medicines to support a sustainable health care system. Lincoln Tsang examines the global environment and suggests it is something that the British medicines and health care products industries will need to bear in mind when considering the prospect of the UK leaving the EU under WTO terms, as some are advocating.
The general secretary of Turkey’s Association of Research based Pharmaceutical Companies (AIFD), Umit Dereli, tells the Pink Sheet why he thinks the government’s policy on local medicines production is wrong in terms of its scope, goal, and method.
As Turkey’s government discloses health care and drug budget plans for 2017, it is becoming clear that controlling the rise in national costs while meeting needs will remain central to policies, prompting the consideration of a variety of approaches.